Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 3
1970 1
1971 1
1972 2
1973 3
1974 2
1975 1
1976 3
1979 1
1980 1
1981 2
1982 3
1983 1
1984 1
1986 6
1987 1
1988 3
1989 4
1990 4
1991 13
1992 7
1993 9
1994 4
1995 4
1996 10
1997 12
1998 15
1999 9
2000 4
2001 12
2002 5
2003 12
2004 14
2005 15
2006 18
2007 12
2008 11
2009 13
2010 9
2011 9
2012 14
2013 13
2014 12
2015 7
2016 7
2017 9
2018 18
2019 11
2020 18
2021 32
2022 30
2023 21
2024 26
2025 36

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

471 results

Results by year

Filters applied: . Clear all
Page 1
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. Jaiyesimi IA, et al. Among authors: furuya n. J Clin Oncol. 2024 Apr 10;42(11):e23-e43. doi: 10.1200/JCO.23.02746. Epub 2024 Feb 28. J Clin Oncol. 2024. PMID: 38417098
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
Miura S, Tanaka H, Misumi T, Yoshioka H, Tokito T, Fukuhara T, Sato Y, Shiraishi Y, Naoki K, Akamatsu H, Yamaguchi O, Yokoyama T, Kuyama S, Nishino K, Furuya N, Kurata T, Kato T, Ikeda S, Horinouchi H, Ichihara E, Mori M, Takiguchi Y, Tanaka K, Goto Y, Okamoto H; Thoracic Oncology Research Group and all ACHILLES investigators. Miura S, et al. Among authors: furuya n. J Clin Oncol. 2025 Jun 20;43(18):2049-2058. doi: 10.1200/JCO-24-02007. Epub 2025 Apr 16. J Clin Oncol. 2025. PMID: 40239133 Clinical Trial.
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, Kumagai S, Shibata Y, Hayashida T, Watanabe K, Fukuhara T, Ikeda T, Yoh K, Kato T, Nishino K, Nakamura A, Nakachi I, Kuyama S, Furuya N, Sakakibara-Konishi J, Okamoto I, Taima K, Ebi N, Daga H, Yamasaki A, Kodani M, Udagawa H, Kirita K, Zenke Y, Nosaki K, Sugiyama E, Sakai T, Nakai T, Ishii G, Niho S, Ohtsu A, Kobayashi SS, Goto K. Izumi H, et al. Among authors: furuya n. Nature. 2021 Dec;600(7888):319-323. doi: 10.1038/s41586-021-04135-5. Epub 2021 Nov 24. Nature. 2021. PMID: 34819663 Free PMC article.
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, Hirai S, Nakamura R, Morimoto K, Furuya N, Arai S, Goto Y, Sakata Y, Nishino K, Tsuchiya M, Tamiya A, Saito G, Muto S, Takeda T, Date K, Fujisaka Y, Watanabe S, Fujimoto D, Uehara H, Horinaka M, Sakai T, Yano S, Tokuda S, Takayama K. Katayama Y, et al. Among authors: furuya n. Clin Cancer Res. 2025 Mar 17;31(6):1127-1141. doi: 10.1158/1078-0432.CCR-24-1762. Clin Cancer Res. 2025. PMID: 39495173
Short Overview.
Furuya N. Furuya N. Methods Mol Biol. 2018;1759:3-8. doi: 10.1007/7651_2017_38. Methods Mol Biol. 2018. PMID: 28497334 Review.
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H. Sugisaka J, et al. Among authors: furuya n. Lung Cancer. 2025 Jan;199:108056. doi: 10.1016/j.lungcan.2024.108056. Epub 2024 Dec 9. Lung Cancer. 2025. PMID: 39674045
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Saito H, et al. Among authors: furuya n. Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8. Lancet Oncol. 2019. PMID: 30975627 Clinical Trial.
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K. Morimoto K, et al. Among authors: furuya n. Lung Cancer. 2025 Mar;201:108447. doi: 10.1016/j.lungcan.2025.108447. Epub 2025 Feb 15. Lung Cancer. 2025. PMID: 39970730
471 results